Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025)
DOI:
https://doi.org/10.17179/excli2025-8694Keywords:
Glioblastoma multiforme, Temozolomide resistance, Oxidative phosphorylation, Gboxin, Cancer metabolism, PLK2, Targeted therapy, Metabolic plasticityDownloads
Published
2025-10-21
How to Cite
Saad, A., & Khan, R. (2025). Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025). EXCLI Journal, 24, 1397–1399. https://doi.org/10.17179/excli2025-8694
License
Copyright (c) 2025 Abdullah Saad, Rameen Khan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
